We are live on ! Find out more
HEPA

Hepion Pharmaceuticals
HEPA

Delisted

HEPA was delisted on the 12th of May, 2025.

Back to rankings

4 hedge funds and large institutions have $377K invested in Hepion Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

63% more capital invested

Capital invested by funds: $231K → $377K (+$146K)

0% more funds holding

Funds holding: 4 → 4 (0)

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
4
Holders Change
–
Holders Change %
0%
% of All Funds
0.09%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
–
Reduced
1
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
+$334K
2
ARTA
A.R.T. Advisors
New York
+$55.1K
3
UBS Group
UBS Group
Switzerland
+$11.6K

Top Sellers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
-$46.4K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$44K
3
Renaissance Technologies
Renaissance Technologies
New York
-$43K
4
Barclays
Barclays
United Kingdom
-$3K
Name Holding Trade Value Shares
Change 		Change in
Stake
SM
1
Sabby Management
Florida
$278K +$334K +115 New
ARTA
2
A.R.T. Advisors
New York
$46K +$55.1K +19 New
VF
3
Virtu Financial
New York
$44K -$46.4K -16 -47%
UBS Group
4
UBS Group
Switzerland
$9K +$11.6K +4 New
Susquehanna International Group
5
Susquehanna International Group
Pennsylvania
– -$44K -11 Closed
Renaissance Technologies
6
Renaissance Technologies
New York
– -$43K -10 Closed
Barclays
7
Barclays
United Kingdom
– -$3K -1 Closed

HEPA Hedge Fund Activity: Q3 2019 in Review

4 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Hepion Pharmaceuticals (HEPA) for Q3 2019, worth a combined $377K — up 63% from $231K a quarter earlier.

Fund positioning in HEPA was balanced in Q3 2019: 3 funds opened new positions, 3 closed out, 0 added to existing stakes and 1 trimmed.

The largest buyer was Sabby Management, opening a new position worth an estimated $334K. The largest seller was Virtu Financial, cutting an estimated $46.4K.

  • 4 institutional investors held Hepion Pharmaceuticals (HEPA) as of Q3 2019, unchanged from Q2 2019.
  • Funds reported $377K of Hepion Pharmaceuticals stock for Q3 2019, up 63% quarter-over-quarter.
  • 3 funds opened new Hepion Pharmaceuticals positions in Q3 2019 and 3 closed out, a net change of 0 holders.
  • The largest Hepion Pharmaceuticals buyer in Q3 2019 was Sabby Management, an estimated $334K added.
  • The largest Hepion Pharmaceuticals seller in Q3 2019 was Virtu Financial, an estimated $46.4K sold.

Based on aggregated 13F filings for Q3 2019.